| |
Redefine what it means to be inspection-ready with Premier’s Inspection Readiness Program. This four-phase plan will arm you with the knowledge, skills, and confidence to successfully host health authority inspections. Get started with our brochure. 
|
|
Today’s Big NewsOct 21, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India. .png)
|
|
| By Nick Paul Taylor Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a midphase clinical trial. |
|
|
|
By James Waldron After launching on its maiden voyage in April, Seaport Therapeutics and its crew of Karuna veterans have loaded up with $225 million in series B funds to support the journey to key clinical milestones for its neuropsychiatric medicines. |
By James Waldron Septerna may still be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor appetite for its G protein-coupled receptors. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
|
- 45 markers for cytokine signaling/inflammation
- Trust RBM for Olink, Luminex & Simoa immunoassays
|
|
By James Waldron Italy’s Angelini Pharma has signed a $360 million biobucks pact to gain regional rights to a phase 1-stage brain health drug from South Korea’s Cureverse. |
Sponsored by TriNetX, Inc. Now’s the time to rethink clinical trials with real-world data (RWD). Discover strategies to optimize your protocols and site selection. |
By Nick Paul Taylor Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match a Vicodin equivalent in one of the studies. |
By Gabrielle Masson The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. |
By James Waldron Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for post-traumatic stress disorder, but the biotech’s new leadership believes the regulator may yet grant the company a path to approval. |
By Darren Incorvaia London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative Medicine at Boston University and Boston Medical Center to develop new models for lung diseases like pulmonary fibrosis. |
By Fraiser Kansteiner As part of a new round of layoffs, certain Takeda staffers at two Massachusetts sites are set to lose their jobs. This marks the third round of job cuts Takeda has initiated in the state since it revealed a large restructuring drive in May. |
By Angus Liu As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the semaglutide drug showed it can provide heart-related benefits, too. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
